This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Dendreon's Aftermath

A classic illustration of this investing rule popped up Wednesday with NuPathe (PATH), developers of a migraine headache patch. On Wednesday morning, NuPathe issued a press release announcing a new common stock purchase agreement in which Aspire Capital Fund had agreed to purchase up to $30 million in NuPathe stock in installments spread over 24 months.

NuPathe, in its press release, said Aspire made an initial investment of $500,000 by acquiring 70,721 shares of NuPathe common stock for $7.07 a share, or a 19% premium to the stock's closing price on Tuesday, Aug. 2.

The impression NuPathe's press release leaves with investors is that Aspire is so confident in the company's future that it was willing to buy stock in the company at above-market price.

Except that's not entirely true, according to NuPathe's materially different disclosure in an accompanying 8-K SEC filing.

NuPathe discloses in its 8-K (but leaves out of the press release) that the company issued 84,866 shares of stock to Aspire in addition to the 70,721 shares purchased. NuPathe calls these 84,866 shares "Commitment Shares." In other words, NuPathe gave Aspire "free" stock valued at $505,000 as an inducement for Aspire to enter into this equity purchase agreement.

The 8-K filing paints a different -- and less rosy -- picture of this equity purchase agreement than what's explained in NuPathe's press release. It's fair to say that Aspire, when the free stock is added to the purchased stock, didn't exactly invest at an above-market price.

In response to questions about the discrepancy between NuPathe's press release and its 8-K filing, CFO Keith Goldan told me that by phone Wednesday that the company could have done a better job with disclosure in its press release. In the company's defense, however, Goldan pointed out that companies routinely pay fees or financial inducements as part of financings or public offerings of stock. With the Aspire deal, Nupathe was able to negotiate a relatively low fee paid in stock rather than cash, said Goldan.

Sure, it's common practice for companies to sweeten the pot for investors in equity or debt financings. Often, a company offers discounted warrants, for example. My counter-point to Goldan, however, was that if NuPathe felt it necessary to trumpet the fact that Aspire purchased stock at an above-market price, the company should have also felt obligated to disclose the inducement it paid Aspire to make the deal happen.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
AMAG $67.14 -4.58%
DNDN $0.06 -6.02%
SPPI $6.56 -5.75%
SGEN $46.87 -1.22%

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs